BACKGROUND The selective serotonin reuptake inhibitors (SSRIs) citalopram, escitalopram, and sertraline are all metabolized by the cytochrome P-450 isoenzyme CYP2C19, which is inhibited by the proton pump inhibitors (PPIs) omeprazole, esomeprazole, lansoprazole, and pantoprazole. The aim of the present study was to evaluate the effect of these PPIs on the serum concentrations of citalopram, esc...

Obsessive-compulsive disorder (OCD) is a common and severe neuropsychiatric disorder treated by both behavioral and pharmacologic techniques. Despite the availability of treatments for OCD, including the selective serotonin reuptake inhibitors (SSRIs), many OCD patients have an inadequate response to current treatments. As such, additional approaches to the management of OCD are required. A pot...

BACKGROUND The aim of this paper is to report maternal and neonatal outcomes in pregnant women treated with escitalopram during pregnancy and breastfeeding. METHODS Women enrolled in the DEGRA Database at the Clinic of Affective Disorders in Pregnancy and Postpartum in Italy, treated during pregnancy with escitalopram and followed up throughout pregnancy, were included in this study. All pati...

OBJECTIVE The aim of this study was to determine the effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes. METHODS A randomized, blinded, multicenter, placebo-controlled parallel-group 8-week trial with 205 women (95 African American, 102 white, 8 other) was conducted between July 2009 and June 2010. The p...

The S-enantiomer of citalopram, escitalopram, is a selective serotonin reuptake inhibitor (SSRI) that appears to be responsible for citalopram's antidepressant and anxiolytic effects. Clinically, escitalopram is reported to have fewer adverse side effects than do other SSRIs. This study compared escitalopram to other antidepressants in a preclinical procedure predicting anxiolytic-like effects ...

BACKGROUND Social Anxiety Disorder (SAD) is a common disorder and its high prevalence and lifelong chronicity are such that it represents a substantial public health problem. The observation that serotonergic agents appear to be effective for its treatment suggests that patients may have abnormal serotonergic neurotransmission within the central nervous system. We investigated the efficacy of E...

The 5-HT (5-hydroxytryptamine, serotonin) transporter (SERT) mediates the reuptake of 5-HT from the synaptic cleft into the neuron, and inhibition of this uptake is the target of selective serotonin reuptake inhibitors (SSRIs). Escitalopram (S-citalopram) is the most selective SSRI available, whereas the other enantiomer, R-citalopram, is approximately 30-40 times less potent than the S-enantio...

About 40% of patients treated with antidepressant do not show a response. However, the underlying mechanisms remain unclear and there is no objective test for the prediction of treatment response. The aim of this study was to investigate the proteomic differences between responder and non-responder in patients with major depressive disorder (MDD who were treated with escitalopram. Fasting blood...

About 40% of patients treated with antidepressant do not show a response. However, the underlying mechanisms remain unclear and there is no objective test for the prediction of treatment response. The aim of this study was to investigate the proteomic differences between responder and non-responder in patients with major depressive disorder (MDD who were treated with escitalopram. Fasting blood...

Three simple, rapid, accurate, precise and cost-effective UV spectrophotometric methods have been developed and validated for simultaneous estimation of Escitalopram oxalate and Etizolam in tablet dosage form. The UV methods have been developed utilizing concept of standard addition utilizing 0.1 N HCl as a solvent. Method I is estimation using simultaneous equation method at 238.2 nm (λmax of ...